Skip to content
In Stock Arava
Rheumatoid Arthritis

Arava

Arava helps reduce abnormal immune activity through leflunomide, a disease-modifying antirheumatic drug (DMARD). It is prescribed for adults with active rheumatoid arthritis and, where clinically…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Leflunomide
Select dosage:
Select pack Package Per unit Price
$ 6.47 $ 194.02
$ 5.22 $ 388.04 $ 313.28 Save 19%
Free Regular Delivery $ 4.79 $ 582.06 $ 430.76 Save 26%
Free Express Delivery $ 4.55 $ 776.08 $ 546.46 Save 30%
Free Express Delivery $ 4.36 $ 1,164.12 $ 784.98 Save 33%
Best value Free Express Delivery $ 4.21 $ 1,746.18 $ 1,137.42 Save 35%
$ 7.59 $ 227.84
Free Regular Delivery $ 6.17 $ 455.68 $ 370.24 Save 19%
Free Regular Delivery $ 5.70 $ 683.52 $ 512.64 Save 25%
Free Express Delivery $ 5.46 $ 911.36 $ 655.04 Save 28%
Free Express Delivery $ 5.21 $ 1,367.04 $ 938.06 Save 31%
Best value Free Express Delivery $ 5.06 $ 2,050.56 $ 1,367.04 Save 33%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Arava helps reduce abnormal immune activity through leflunomide, a disease-modifying antirheumatic drug (DMARD). It is prescribed for adults with active rheumatoid arthritis and, where clinically appropriate, psoriatic arthritis, with benefits developing gradually rather than as immediate pain relief.

Product information

Arava contains leflunomide and belongs to the DMARD group. These medicines change inflammatory disease activity instead of simply masking pain. Arava tablets are used under medical supervision when inflammatory arthritis needs sustained control.

Ingredients

Composition and Drug Class

Leflunomide is an oral pyrimidine synthesis inhibitor. It limits the activity of immune cells involved in persistent joint inflammation. The Australian Product Information describes Arava as a treatment for active rheumatoid arthritis and psoriatic arthritis in suitable adults.

A DMARD aims to reduce disease activity over time and help preserve joint function. It does not work like a simple painkiller, and symptom relief may take several weeks.

Therapeutic indications

Arava contains leflunomide and belongs to the DMARD group. These medicines change inflammatory disease activity instead of simply masking pain. Arava tablets are used under medical supervision when inflammatory arthritis needs sustained control.

Product fact Clinical meaning
Active ingredient Leflunomide
Drug class Disease-modifying antirheumatic drug
Main disease areas Active rheumatoid arthritis and selected cases of psoriatic arthritis

Rheumatoid Arthritis Treatment

For rheumatoid arthritis, treatment decisions depend on disease severity, affected joints, previous medicines, blood-test results, liver health and other medical conditions. Arava may be considered when a conventional DMARD is appropriate for controlling active inflammatory disease.

The aim is not only to make joints feel better. Reduced inflammation can support movement and help limit the progression of joint damage when treatment achieves adequate disease control.

Psoriatic Arthritis Treatment

Arava may be used for active psoriatic arthritis when the inflammatory joint component requires a DMARD. Psoriatic skin, nail and spinal features may need separate treatment planning because one medicine may not control every part of the condition.

Arava is intended for sustained disease control. A better pain day does not automatically mean that inflammatory activity has stopped or that blood monitoring can be discontinued.

Directions for use

The amount used and the frequency of treatment depend on the purpose of use and are agreed with a doctor or pharmacist. Arava tablets should be taken only according to the prescribed regimen.

Daily Administration

  • Take the tablet at the prescribed time each day.
  • Swallow it as directed with water.
  • Food does not usually determine the timing, unless the prescriber gives different instructions.
  • Do not change, split or stop treatment without medical advice.
  • Do not take two tablets to compensate for a missed dose.
  • Keep scheduled blood tests, even when joint symptoms improve.

Some adult regimens include a clinician-directed loading phase followed by a daily maintenance dose. A loading dose is not suitable for every patient because the prescriber weighs disease urgency, tolerability and safety factors.

If a dose is missed, take it when remembered unless the next dose is due soon. Skipping the missed dose is safer than doubling. A pharmacist or prescriber can give the exact instruction when the timing of the missed dose is unclear.

The tablet can be easy to forget when arthritis symptoms settle. Linking the dose with a regular daily routine, such as breakfast, can reduce missed doses without changing the prescribed schedule.

Treatment Response Timeline

Arava is intended to reduce inflammatory disease activity progressively. Rheumatoid arthritis or psoriatic arthritis symptoms may begin to improve after several weeks, while the full response can take longer.

Pain can fluctuate for reasons unrelated to DMARD activity. A temporary improvement after one dose should not be interpreted as immediate disease control, and ongoing swelling or morning stiffness should be reported during review.

When not to use it

Arava should not be used without specialist assessment in situations such as:

  • Significant liver impairment or active liver disease
  • Severe immune deficiency
  • A serious active infection
  • Severe abnormalities of white cells, red cells or platelets
  • Pregnancy or a plan to become pregnant
  • Breastfeeding when treatment has not been specifically assessed
  • A previous serious reaction to leflunomide or its active metabolite

Important groups include:

  • Other medicines that can injure the liver
  • Other immunosuppressants
  • Medicines that can affect blood counts
  • Treatments for serious infections
  • Selected live vaccines

When this is not for you

Arava is not suitable for everyone. Medical review is needed before treatment when there is a history of liver disease, significant immune deficiency, serious infection or abnormal blood counts.

Pregnancy planning requires special attention because leflunomide and its active metabolite may persist in the body. If pregnancy occurs during treatment, urgent medical advice is required. A clinician may prescribe an accelerated drug-elimination procedure and follow-up testing; the timing and medicines must be supervised.

Tell the prescriber about all medicines, including non-prescription products and supplements.

The immune system may respond differently to vaccination during DMARD therapy. Vaccine timing should be discussed before treatment, and live vaccines require specific medical assessment.

Unwanted effects

Arava can affect the liver, blood cells, blood pressure, skin, hair and gastrointestinal system. The Australian Product Information lists diarrhoea, nausea, headache, rash, hair thinning and raised blood pressure among recognised adverse effects.

Common Adverse Effects

Possible effects include:

  • Diarrhoea or loose stools
  • Nausea or reduced appetite
  • Headache
  • Skin rash or itching
  • Hair thinning
  • Raised blood pressure
  • Tiredness
  • Mild respiratory or other infections

Persistent diarrhoea, repeated vomiting or a troublesome rash should be discussed promptly. Do not manage persistent symptoms by stopping and restarting tablets independently, because leflunomide remains in the body for an extended period.

Hair thinning can be distressing even when it is not medically dangerous. Mentioning it early gives the clinician an opportunity to review the timing, severity and other possible causes.

Liver Safety Checks

Leflunomide may cause liver injury. Liver function tests are generally performed before treatment and repeated during treatment at intervals determined by the prescriber and Australian monitoring guidance.

Urgent medical assessment is needed for:

  • Yellowing of the skin or eyes
  • Dark urine
  • Severe or unusual fatigue
  • Persistent vomiting
  • Pain under the right ribs
  • Marked loss of appetite
  • Severe or spreading rash

Abnormal liver results may require dose review, treatment interruption or an accelerated elimination procedure under medical supervision. Alcohol intake and other medicines that affect the liver should be discussed before treatment begins.

Liver problems can develop without early pain. A missed blood test is not merely an administrative issue; it can remove the chance to detect a silent abnormal result before it becomes serious.

Serious Infection and Blood-Count Symptoms

Immune modulation can increase susceptibility to infection. Fever, chills, breathlessness, painful urination, a worsening cough or a wound that is not healing needs prompt clinical attention.

Blood-count changes may present as unusual bruising, recurrent infections, mouth ulcers, pale skin or marked weakness. These symptoms need medical review rather than self-treatment with supplements or leftover medicines.

Mechanism of action

Leflunomide reduces the ability of activated lymphocytes to multiply. These immune cells can drive ongoing inflammation in rheumatoid arthritis and psoriatic arthritis.

Pyrimidine Synthesis Inhibition

Inside cells, leflunomide is converted to an active metabolite that inhibits dihydroorotate dehydrogenase. This enzyme is needed for pyrimidine production, which activated lymphocytes require when they divide.

A simple analogy is a supply restriction: the medicine reduces access to a building material needed for rapid immune-cell expansion. It does not switch off the entire immune system.

Immune System Modulation

By limiting activated lymphocyte proliferation, Arava can reduce inflammatory signalling in affected joints. The same immune modulation explains why infection symptoms, blood-count changes and vaccination plans require attention during treatment.

Clinical rheumatology guidance from the European Alliance of Associations for Rheumatology (EULAR) places leflunomide among conventional synthetic DMARDs used to control inflammatory arthritis, with treatment choice guided by disease activity and patient-specific risks.

Common mistakes

  • Missing blood tests: Liver or blood-count abnormalities may be silent. Arrange the required monitoring before the next review date.
  • Doubling after a missed tablet: A double dose does not restore the schedule and may increase adverse effects. Follow the missed-dose instruction instead.
  • Stopping suddenly after improvement: Symptom relief does not prove that inflammatory disease has become inactive.
  • Ignoring alcohol intake: Alcohol can add to liver stress. Discuss regular or heavy drinking before treatment.
  • Starting supplements without checking: Herbal products and non-prescription medicines may affect the liver or interact with other treatment.
  • Forgetting the prolonged persistence of leflunomide: Stopping a tablet does not remove the medicine immediately.
  • Assuming diarrhoea is harmless: Persistent diarrhoea can require assessment, especially when accompanied by weakness or dehydration.
  • Failing to report infection symptoms: Fever, breathlessness and worsening cough need prompt attention during immune-modulating treatment.
Keep a simple record of blood-test dates, new medicines, unusual bruising, infections and changes in bowel symptoms. This gives the prescriber useful information without relying on memory during a short appointment.

Comparison

Arava is one option within conventional DMARD treatment. Methotrexate, sulfasalazine and biologic DMARDs differ in route, monitoring requirements, onset and safety considerations.

Treatment category Route and monitoring focus Main limitation
Leflunomide Oral tablet; liver function, blood pressure and blood counts Liver toxicity, infection risk and prolonged persistence
Methotrexate or sulfasalazine Oral or injectable methotrexate; oral sulfasalazine; blood monitoring Different organ risks, tolerability issues and pregnancy restrictions
Biologic DMARDs Injection or infusion; infection screening and specialist monitoring Higher treatment complexity and infection precautions

Conventional DMARD Comparison

Methotrexate is often considered in inflammatory arthritis treatment pathways, but it has its own liver, blood-count, lung and pregnancy precautions. Folate supplementation is commonly considered with methotrexate under clinical direction.

Sulfasalazine may be useful in selected rheumatoid arthritis or psoriatic arthritis patterns. Its monitoring and adverse-effect profile differs from leflunomide.

Treatment selection depends on disease pattern, previous response, liver and kidney health, infection history, pregnancy plans and patient preference. Switching between DMARDs requires a planned regimen.

Biologic DMARD Treatment Pathways

Biologic DMARDs target specific immune pathways and may be considered when conventional treatment does not control disease adequately. Specialist assessment commonly includes disease activity scores, previous treatment response and infection screening.

A biologic is not automatically a stronger or more suitable choice. The most appropriate treatment depends on the inflammatory pattern and the safety profile for that individual.

What doctors say

In clinical practice, doctors assess Arava through more than pain scores. They look at swollen joints, morning stiffness, movement, fatigue, blood results, blood pressure and the patient’s ability to manage everyday tasks.

A rheumatologist would usually explain that the medicine needs time to modify inflammatory activity. The patient may still need a separate plan for pain during the early treatment period, since Arava does not provide instant analgesia.

Clinicians also pay close attention to liver risk and infection symptoms. A patient who feels well still needs monitoring because liver and blood-count abnormalities may appear before noticeable symptoms. These findings are reviewed against disease activity over time. Monitoring also helps identify safety problems before they become severe. Treatment decisions can then reflect both benefit and risk.

The World Health Organization describes DMARD treatment as part of long-term management for inflammatory rheumatic disease, while local prescribing decisions remain guided by the Australian Product Information and specialist assessment.

What customers often ask

What happens when Arava is stopped, and does it need tapering?

Leflunomide is not usually tapered like a corticosteroid, but stopping Arava still requires a planned medical decision. Its active metabolite can remain in the body for a prolonged period, so stopping tablets does not produce immediate clearance. The EMA product information states that an accelerated elimination procedure may be used in situations such as severe toxicity or pregnancy exposure. The Australian Product Information remains the key reference for local treatment decisions in 2026.

How soon does Arava become noticeable?

Arava usually works gradually because it changes activated immune-cell activity rather than acting as an immediate pain reliever. Some people notice changes after several weeks, while a fuller response may require longer treatment. The 2018 NICE rheumatoid arthritis guidance supports assessing DMARD response through disease activity and function, not through one isolated good or bad day. Persistent swelling or stiffness should be reported even if pain has reduced.

What should I do after a missed Arava dose?

Take the missed tablet when remembered unless the next scheduled dose is close. In that situation, skip the missed dose and resume the normal schedule; do not double the amount. The 2024 TGA-approved Australian Product Information gives the basis for missed-dose instructions and overdose precautions. Contact a pharmacist or prescriber promptly if two doses were taken accidentally or if the timing is uncertain.

Which concrete condition rules Arava out?

Active significant liver disease is a major reason Arava may be unsuitable. Pregnancy and serious active infection also require urgent medical assessment before treatment continues. The 2024 EMA product information identifies liver toxicity, blood abnormalities and pregnancy-related precautions within the leflunomide safety framework. A history of liver disease should be disclosed before the first dose, even when recent symptoms are absent.

Can I drive, concentrate or work with machinery while taking Arava?

Arava does not automatically prevent driving or operating machinery, but dizziness, headache, weakness, visual symptoms or severe fatigue can make those activities unsafe. Avoid driving or machinery work while such symptoms affect alertness or coordination. The TGA’s Australian product information remains the relevant reference for medicine-related precautions in 2026. Alcohol can worsen impairment and may also increase liver stress.

How long does one Arava dose keep working?

The clinical effect of a single tablet is not measured like the short action of a painkiller. Leflunomide’s active metabolite has a long persistence, and the disease-modifying benefit depends on continued treatment rather than one isolated dose. The 2024 EMA product information describes the need for an accelerated elimination procedure when rapid removal is clinically required. Never take extra tablets to create a faster effect.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Arava Current

Active ingredient: Leflunomide
10mg 20mg
From $ 194.02
pills
3.6 (4)

Humira

Active ingredient: Adalimumab
20mg0.4ml 40mg0.8ml
From $ 1,343.90
injectors
3.8 (3)

Plaquenil

Active ingredient: Hydroxychloroquine
200mg 400mg
From $ 89.00
pills
4.2 (5)

How the medicines for Rheumatoid Arthritis compare

How Buyers Rate Arava

Based on 4 reviews

James, 49 Verified
Rating: 3.5 out of 5

I used Arava for rheumatoid arthritis for several months. My hands became less stiff by about the sixth week, but diarrhoea was troublesome at first and my doctor adjusted the plan after reviewing my blood tests.

Several months 5 Oct 2026
Christopher, 36 Verified
Rating: 3.5 out of 5

The tablets were easy to take and I noticed better movement in the mornings after roughly two months. I still had occasional flares, so I learned that feeling better did not mean I could skip monitoring.

Roughly two months 16 Oct 2026
Craig, 50 Verified
Rating: 4 out of 5

My joints improved, but hair thinning became noticeable and worried me. It did not lead to an emergency, although discussing it early helped my rheumatology team decide whether to continue.

25 Oct 2026
Daniel R., 58 Verified
Rating: 3.5 out of 5

I missed a blood test because I was travelling and delayed contacting the clinic. Nothing felt wrong, but the appointment was rearranged before I continued the next part of treatment.

1 Nov 2026
Get our free app Shop faster and track your orders 3.8 · 494 reviews Install